Crinone8%

Crinone is a natural progestin hormone used in the following clinically established indications:

• Secondary amenorrhea: Used to induce withdrawal bleeding in women who have not menstruated due to a hormonal imbalance (progestational challenge test/therapy), provided pregnancy and other causes have been excluded.
• Abnormal uterine bleeding due to hormonal imbalance: Used to regulate irregular or dysfunctional uterine bleeding when no structural or malignant cause is identified.
• Prevention of endometrial hyperplasia: Used together with estrogen replacement therapy in non-hysterectomized postmenopausal women to oppose estrogen's proliferative effect on the endometrium.
• Luteal phase support in assisted reproductive technology (ART): Used as part of fertility treatment protocols (e.g., in vitro fertilization) to support the uterine lining after egg retrieval/embryo transfer, typically as an adjunct to other fertility medications.
• Maintenance of pregnancy in threatened or recurrent (habitual) abortion: Used under specialist supervision in selected cases of luteal insufficiency; this is a distinct, specialist-directed use separate from the general non-pregnancy contraindication described in Contraindications.

Some additional uses (e.g., premenstrual syndrome symptom management, benign breast conditions) are supported by limited or mixed evidence and should only be undertaken on a physician's advice.

Each formulation contains Progesterone (natural, micronized) as the active ingredient. Available forms include oral capsules (100 mg, 200 mg), vaginal gel, vaginal pessary/suppository, and subcutaneous injection (25 mg/1.119 mL). Oral micronized capsules commonly use peanut (arachis) oil as a vehicle - patients with peanut allergy must avoid this form. Excipient composition varies by brand and dosage form; refer to the specific product's packaging for full excipient details.

Crinone is an endogenous steroid hormone belonging to the progestin class, produced naturally by the corpus luteum, placenta, and adrenal glands. Pharmaceutical Crinone is chemically and biologically identical to the hormone produced by the body ("micronized" to improve absorption) and is used to replace or supplement natural Crinone in conditions of hormonal deficiency or imbalance affecting the female reproductive system.

Crinone is available as oral capsules, vaginal gel, vaginal pessaries, and subcutaneous injection, allowing the route of administration to be tailored to the specific indication and patient tolerance.

Crinone belongs to the therapeutic class of progestins (natural progestogens), a subclass of female sex hormones used in gynecology, reproductive endocrinology, and hormone replacement therapy.

Progesterone is the principal progestational hormone secreted by the ovary. It acts on progesterone receptors in the endometrium, myometrium, breast, and hypothalamus/pituitary to:

• Convert proliferative endometrium (built up by estrogen) into secretory endometrium, preparing it for implantation.
• Reduce uterine excitability and contractility (myometrial quiescence).
• Oppose estrogen-driven endometrial proliferation, reducing the risk of endometrial hyperplasia.
• Provide negative feedback on gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) secretion.

Oral micronized Progesterone undergoes extensive first-pass hepatic metabolism, producing metabolites (including allopregnanolone) responsible for its sedative/hypnotic side effect, which is why oral doses are often given at bedtime. Vaginal and subcutaneous routes achieve higher local/systemic bioavailability with less sedation.

Oral capsules: Swallow whole with water, preferably at bedtime, on an empty stomach, due to drowsiness. Vaginal gel/pessary: Insert into the vagina using the applicator provided, typically once or twice daily as directed. Subcutaneous injection: Inject into the abdominal skin as instructed by a healthcare provider, rotating injection sites to reduce local irritation. Do not change the route of administration or dose without consulting the prescribing physician.

Crinone has the following clinically significant interactions:

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, certain macrolide antibiotics): may increase Crinone blood levels, increasing risk of side effects.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St. John's Wort): may reduce Crinone effectiveness by increasing its metabolism.
• Other hepatic enzyme-metabolized drugs: Crinone may compete for or affect hepatic metabolic pathways; caution advised with other hormonal agents.
• CNS depressants (sedatives, benzodiazepines, alcohol): additive drowsiness/sedation may occur with oral Crinone, particularly at higher doses.

Inform the prescribing physician of all concurrent medications before starting Crinone.

Common side effects of Crinone include:

• Somnolence, dizziness, or drowsiness (particularly with oral capsules, which is why bedtime dosing is recommended)
• Breast tenderness or swelling
• Headache
• Mood changes, irritability, or depression
• Bloating, abdominal discomfort, or fluid retention
• Nausea
• Local irritation, itching, or discharge (with vaginal forms) or injection site reactions (with subcutaneous injection)

Side effects are generally less pronounced with vaginal or subcutaneous routes compared to oral administration. Contact a physician if side effects are severe or persistent, or if symptoms of a blood clot (leg swelling/pain, chest pain, sudden shortness of breath) occur - see Contraindications.

Pregnancy: Crinone is used therapeutically in specific, specialist-directed pregnancy-support indications (luteal support in ART, threatened/recurrent abortion due to luteal insufficiency). Outside these specific indications, Crinone should not be used in known or suspected pregnancy. When used for pregnancy support, it should be under the direct supervision of an obstetrician or fertility specialist who has weighed the potential benefits against potential risks for that individual.

Lactation: Small amounts of Crinone pass into breast milk. Use during breastfeeding should occur only if clearly needed and if the potential benefit justifies the potential risk to the infant; consult a physician before use while breastfeeding.

Use Crinone with caution in patients with:

• A history of depression or mood disorders - monitor mood during treatment.
• Conditions predisposed to fluid retention, such as cardiac or renal dysfunction, epilepsy, or migraine, as Crinone may cause fluid retention and worsen these conditions.
• Diabetes mellitus - Crinone may affect glucose tolerance; monitor blood glucose.
• A history of jaundice or hepatic impairment (short of active liver disease, which is an absolute contraindication - see Contraindications).

Crinone capsules may cause drowsiness; patients should avoid driving or operating machinery until they know how the medicine affects them, particularly after bedtime dosing. Periodic clinical evaluation (including breast and pelvic examination) is recommended during long-term therapy.

Overdose with Crinone may cause exaggerated side effects such as marked drowsiness, dizziness, nausea, or vomiting. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, and should be managed by a healthcare professional.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze injectable or gel formulations unless specifically directed by the manufacturer's labeling.

Renal impairment: Use with caution; Crinone may worsen fluid retention in significant renal dysfunction. No specific dose adjustment is well established; individualize therapy.

Hepatic impairment: Contraindicated in active liver disease (see Contraindications); use with caution and close monitoring in mild hepatic impairment, as Crinone is extensively hepatically metabolized.

Elderly: Crinone is not typically indicated for use in elderly men or women outside of hormone replacement therapy contexts; safety and efficacy in the elderly population beyond approved indications have not been specifically established.

Pediatric: Not indicated in children; safety and efficacy have not been established (see Pediatric Uses).

Duration of Crinone therapy depends on the indication: typically 10 days per cycle for inducing withdrawal bleeding in secondary amenorrhea; 12 days per 28-day cycle for endometrial protection with estrogen therapy; and from the time of embryo transfer until approximately 10-12 weeks of gestation for luteal support/pregnancy maintenance in ART or threatened abortion. The treating physician determines the exact duration based on indication and clinical response.

Progesterone belongs to the drug class of natural progestins (progestogens), a subgroup within female sex hormones.

Progesterone binds to intracellular progesterone receptors in target tissues (endometrium, myometrium, breast, hypothalamus), converting estrogen-primed proliferative endometrium into a secretory state suitable for implantation, reducing uterine muscle contractility, and providing negative feedback to the hypothalamic-pituitary axis to suppress LH/FSH surges. These actions underlie its use in regulating menstrual cycles, supporting the endometrial lining in fertility treatment, and preventing estrogen-induced endometrial overgrowth.

Crinone is not indicated for use in children or adolescents prior to menarche. Safety and efficacy of Crinone in pediatric patients have not been established, and it should not be used in this population outside of rare, specialist-directed circumstances (e.g., certain pediatric endocrinology settings), which are beyond the scope of routine use.